drugset / Trial / NCT04957940

Lipid Emulsion Infusion and COVID-19 Patients

NCT04957940

Phase 3 Completed 74 enrolled Assiut University
RandomizedParallel-groupDouble-blindTreatment

Summary

Investigators suggest that early administration of intravenous lipid emulsion (ILE) affect the inflammatory response and improve outcome in COVID-19. The aim of this trial is to study the effect of fish-oil-based intravenous lipid emulsion (FOBLE) supplementation added to enteral nutrition on shift to ICU for upgrading oxygenation \&/or ventilation in moderate cases of Covid-19 diseased patients requiring only supplemental oxygen in form of simple nasal cannula or venturi mask oxygen (during 7 days admission).

Timeline

Start
2021-07-05
Primary completion
2021-09-20
Completion
2021-09-26

Drugs

EvaluationDrugModalityDoseRoute
Subject SMOFlipid Other / unclassified 100 ml Intravenous

Indications